QCM Cayman’s Novo Nordisk NVO Stock Holding History

QCM Cayman’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,044	Closed	-$209K	–	222
2016 Q3	$209K	Buy	+10,044	New	+$249K	0.23%	145

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $146B AUM 55.73% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

QCM Cayman's NVO Position: Q4 2016 in Review

QCM Cayman sold out of Novo Nordisk (NVO) in Q4 2016, closing a stake of 10,044 shares — an estimated $209K sold.

QCM Cayman first reported a position in NVO in Q3 2016 and held it in 1 quarter. The position peaked at $209K in Q3 2016. 483 funds tracked by Wall St. Rank hold NVO as of Q4 2016.

QCM Cayman reported no remaining Novo Nordisk position as of Q4 2016 after selling out during the quarter.
QCM Cayman sold 10,044 Novo Nordisk shares in Q4 2016, an estimated $209K.
QCM Cayman first reported a position in Novo Nordisk in Q3 2016 and held it in 1 quarter.
QCM Cayman's Novo Nordisk position peaked at $209K in Q3 2016.
483 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2016.

Based on QCM Cayman's 13F filing for Q4 2016, filed 14 Feb 2017.